Answers are grounded in this paper and cite their sources.
This 5‐year update of a study by the Southwest Oncology Group continues to show that combination chemotherapy utilizing cyclophosphamide, methotrexate, 5‐fluorouracil, vincristine, and prednisone (CMFVP) is superior to melphalan (L‐PAM) used alone. Adjuvant chemotherapy for patients with operable breast cancer and positive axillary nodes treated with continuous CMFVP confers a significantly longer disease‐free and total survival compared to those treated with intermittent L‐PAM. This significant decrease in recurrence and prolongation of survival are demonstrated for the entire CMFVP group and in the following subgroups: premenopausal, postmenopausal, and women with 4 or more axillary nodes. Women with 1 to 3 axillary nodes have a significantly longer disease‐free interval, but a total survival advantage is not statistically significant .
No takes yet. Share an insight, caveat, or question.
Rivkin et al. (1985) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: